On March 25, 2025 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported four preclinical poster presentations at the upcoming 2025 AACR (Free AACR Whitepaper) Annual Meeting being held in Chicago, IL April 25-30, 2025 (Press release, Cogent Biosciences, MAR 25, 2025, View Source [SID1234651416]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Details
Title: Identification of a potent KRAS (ON) inhibitor with selectivity for mutant KRAS over HRAS and NRAS
Session Category: Chemistry
Session Title: Lead Identification and Optimization
Session Date and Time: April 30, 2025 – 9:00 AM – 12:00 PM CT (10:00 AM – 1:00 PM ET)
Location: Poster Section 25
Poster Board Number: 3
Published Abstract Number: 6974
Title: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor
Session Category: Experimental and Molecular Therapeutics
Session Title: Kinase and Phosphatase Inhibitors 2
Session Date and Time: April 28, 2025 – 2:00 PM – 5:00 PM CT (3:00 PM – 6:00 PM ET)
Location: Poster Section 20
Poster Board Number: 5
Published Abstract Number: 3004
Title: The Reversible and Selective FGFR2/3 inhibitor CGT4859 has superior target coverage of resistance mutations missed by leading FGFR inhibitors
Session Category: Clinical Research
Session Title: Targeted Therapies and Combinations 2
Session Start: April 29, 2025 – 9:00 AM – 12:00 PM CT (10:00 AM – 1:00 PM ET)
Location: Poster Section 34
Poster Board Number: 27
Published Abstract Number: 4729
Title: Identification of CGT4255 an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 3
Session Start: April 29, 2025 – 2:00 PM – 5:00 PM CT (3:00 PM – 6:00 PM ET)
Location: Poster Section 21
Poster Board Number: 1
Published Abstract Number: 5623
Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cogent also announced today that the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grant of an "inducement" equity award on March 21, 2025 to one new employee under the company’s 2020 Inducement Plan. The award was approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employee received a nonqualified option to purchase 9,700 shares of Cogent common stock. The option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a 4-year vesting schedule with 25% vesting on the 1-year anniversary of the grant date and the remainder vesting in equal monthly installments over the subsequent 36 months, provided such employee remains employed through each such vesting date.